Teucrium Corn Fund vs Merck & Co., Inc. — how do they compare? Teucrium Corn Fund trades at $19.05 (market cap $125.39M), while Merck & Co., Inc. trades at $144.92 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 2801.5× Teucrium Corn Fund's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Teucrium Corn Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Teucrium Corn Fund for 26 Days and Merck & Co., Inc. for 98 Days on average.
| CORN | MRK | |
|---|---|---|
Market Cap | $125.39M | $351.28B |
Volume | 271,634 | 7,969,665 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $20.29 | $156.43 |
52-Week Low | $16.46 | $82.49 |
Typical Hold Time | 26 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →